The EVERY Company, a San Francisco-based food technology company, has been awarded $2 million from the US Department of Defense to explore US-based manufacturing. The grant will be used to conduct a feasibility assessment for a site in the United States to manufacture EVERY’s two core proteins: a highly soluble protein for protein-boosting, and ovalbumin for functional egg and egg white replacement. The DoD’s investment is part of the Distributed Bioindustrial Manufacturing Program, which seeks to boost US biomanufacturing capabilities in five critical areas for national security: fabrication, firepower, fitness, food, and fuel.
“Investing in biomanufacturing will allow the United States to safeguard reliable domestic supply chains, reduce reliance on foreign imports, and establish itself as a leader in food technology,” remarked EVERY’s CEO, Arturo Elizondo. The company has been manufacturing its proteins overseas in Europe and Asia, and this award will enable EVERY to expand its presence in its home country and strengthen US biomanufacturing. EVERY plans to develop military use-cases for its proteins, primarily using its soluble protein to deliver high-quality nutrition in high-density formats.
Dod grant boosts EVERY’s US manufacturing
“Our technology allows us to bring novel applications to market using our soluble protein. Imagine a glass of water that looks and tastes like water, but contains 20 grams of protein.
That’s what our protein can do,” says Elizondo. EVERY has consistently demonstrated its process at an industrial scale greater than 100,000 liters, obtained US FDA approval for all its proteins, and successfully commercialized its entire portfolio. “Our focus for the next 12 months will be on entering the mass market,” notes the CEO.
“This award will allow us to work towards expanding our production capacity to meet the needs of most of our customers, who require thousands of metric tons of product.”
EVERY’s production process uses a fraction of the land and water required to produce conventional protein and utilizes US-grown corn as its primary feedstock, stimulating the US rural economy. This announcement comes less than a month after EVERY was granted a pioneering patent covering the use of ovalbumin in a broad range of applications and follows several partnership announcements with multinationals, including Colombia’s largest food company and the world’s top producer of Spanish omelets.
